The key to any valuable company is the leadership with abilities to accomplish goals.
Board of Directors
Jeffrey S. Conrad, Secretary and Director
Mr. Conrad currently serves as Secretary of the Company as well as a Director. He has been a director of the Company since June of 2007. Mr. Conrad is a securities attorney and partner in eFund Capital Management, LLC. He has accumulated successful experience in all facets of investment banking including portfolio management, mergers and acquisitions, financial analysis, and legal analysis. He was formerly with Gibson, Dunn and Crutcher and Universal Pictures. Mr. Conrad is a graduate of the University of California, Los Angeles and received his Juris Doctorate degree from Loyola Law School.
Barrett R. Evans
Mr. Evans has been a director of the Company since June of 2007. Mr. Evans is eFund Capital Management’s managing partner. He began his career with Cruttenden Roth, a California regional emerging growth focused investment bank. He has significant relationships with institutional investors in private equity and debt offerings and has engaged in all facets of investment banking from private debt and equity financing to Initial Public Offerings, retail brokerage and institutional trading, Mezzanine financing and bridge capital. Mr. Evans is a graduate of the University of California, Santa Barbara.
Advisory Board
John D. Todd, B.Sc., M.D., F.R.C.S., Clinical Advisory Board Chairman, Scientific Advisor
Dr. Todd is a Scientific Advisor to Genesis Bioventures and serves as Chairman of the Genesis Bioventures' Clinical Advisory Board. Dr. Todd received his medical training in Calgary, Alberta and currently maintains a general surgical practice at the Peace Arch Hospital in White Rock, British Columbia, specializing in the care of breast cancer patients. Dr. Todd served as Chief of Surgery at the Peace Arch Hospital for nine years and has been instrumental in establishing effective, thorough management of breast cancer patients, including award winning community support programs. Dr. Todd previously conducted studies with Genesis Bioventures to demonstrate the value of mammastatin and found that the naturally occurring protein regulates cell growth of breast tissue and appears to halt the growth of malignancies that arise from breast tissue. Dr. Todd received Health Canada approval to administer the mammastatin protein as a therapeutic to treat seven palliative women who were dying of breast cancer and found a significant remission being demonstrated in several patients. This research led Dr. Todd to enter the field of biomedical research and he subsequently co-founded ProtoKinetix, Inc., a public biotech company of which he served as President and Chief Executive Officer until May of 2007.